

ALEXION PHARMACEUTICALS INC

Form 4

October 11, 2005

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**LINK MAX**

(Last) (First) (Middle)

**C/O ALEXION  
PHARMACEUTICALS INC., 352  
KNOTTER DRIVE**

(Street)

**CHESHIRE, CT 06410**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol  
**ALEXION PHARMACEUTICALS  
INC [ALXN]**3. Date of Earliest Transaction  
(Month/Day/Year)  
**10/10/2005**4. If Amendment, Date Original  
Filed(Month/Day/Year)5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value \$.0001	10/10/2005		P		2,400	A	\$ 26.62
Common Stock, par value \$.0001	10/10/2005		P		300	A	\$ 26.63
Common Stock, par	10/10/2005		P		300	A	\$ 26.64

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

value \$.0001							
Common Stock, par value \$.0001	10/10/2005	P	400	A	\$ 26.65	46,057	D
Common Stock, par value \$.0001	10/10/2005	P	500	A	\$ 26.66	46,557	D
Common Stock, par value \$.0001	10/10/2005	P	100	A	\$ 26.67	46,657	D
Common Stock, par value \$.0001	10/10/2005	P	100	A	\$ 26.68	46,757	D
Common Stock, par value \$.0001	10/10/2005	P	700	A	\$ 26.7	47,457	D
Common Stock, par value \$.0001	10/10/2005	P	500	A	\$ 26.71	47,957	D
Common Stock, par value \$.0001	10/10/2005	P	100	A	\$ 26.73	48,057	D
Common Stock, par value \$.0001	10/10/2005	P	100	A	\$ 26.74	48,157	D
Common Stock, par value \$.0001	10/10/2005	P	100	A	\$ 26.78	48,257	D
Common Stock, par value \$.0001	10/10/2005	P	500	A	\$ 26.79	48,757	D
Common Stock, par value	10/10/2005	P	200	A	\$ 26.8	48,957	D

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

\$.0001

Common  
Stock, par  
value

10/10/2005

P

100

A

\$  
26.81

49,057

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

6,000

A

\$  
26.82

55,057

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

300

A

\$  
26.83

55,357

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

100

A

\$  
26.84

55,457

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

300

A

\$  
26.85

55,757

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

100

A

\$  
26.86

55,857

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

160

A

\$  
26.89

56,017

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

100

A

\$ 26.9

56,117

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

100

A

\$  
26.92

56,217

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

1,040

A

\$  
26.93

57,257

D

\$.0001

Common  
Stock, par  
value

10/10/2005

P

400

A

\$  
26.94

57,657

D

\$.0001

# Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

LINK MAX  
C/O ALEXION PHARMACEUTICALS INC.  
352 KNOTTER DRIVE  
CHESHIRE, CT 06410

X

## Signatures

/s/ Max Link

10/11/2005

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.